• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

玻璃体腔注射曲安奈德治疗糖尿病性黄斑水肿在已行玻璃体切割术和未行玻璃体切割术的眼中眼压的比较。

Comparison of the intraocular pressure following an intravitreal triamcinolone acetonide injection for diabetic macula oedema in vitrectomised and non-vitrectomised eyes.

作者信息

Orii Yusuke, Gozawa Makoto, Takamura Yoshihiro, Takeuchi Yuko, Morioka Masakazu, Yamada Yutaka, Matsumura Takehiro, Sugimoto Masahiko, Inatani Masaru

机构信息

Department of Ophthalmology, University of Fukui Faculty of Medical Sciences, Yoshida-gun, Japan.

Ophthalmology, Tokyo Dental College, Ichikawa General Hospital, Chiba, Japan.

出版信息

BMJ Open Ophthalmol. 2021 Jan 8;6(1):e000620. doi: 10.1136/bmjophth-2020-000620. eCollection 2021.

DOI:10.1136/bmjophth-2020-000620
PMID:33490603
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7798713/
Abstract

PURPOSE

To compare the intraocular pressure (IOP) after an intravitreal triamcinolone acetonide (IVTA) between vitrectomised and non-vitrectomised eyes in patients with diabetes and diabetic macular oedema (DME).

DESIGN

Retrospective comparative study.

METHODS

Medical records of 157 patients (157 eyes) with type 2 diabetes who received IVTA for DME were reviewed, and the best-corrected visual acuity, IOP and optical central retinal thickness (CRT) were compared preoperatively, at 1, 4, 12 and 24 weeks after IVTA between the vitrectomised and non-vitrectomised groups.

RESULTS

IOP significantly increased at 1 (p<0.0001), 4 (p<0.0001), 8 (p<0.0001), 12 (p=0.0019), 16 (p=0.0006) and 20 weeks (p=0.0191) in the non-vitrectomised group, whereas a significant increase was only observed at 1 (p=0.0003) and 4 weeks (p=0.0006) in the vitrectomised group. ΔIOP, IOP changes from baseline, in the non-vitrectomised group was significantly higher than that in the vitrectomised group at 4 (p=0.0014), 8 (p=0.0081), 12 (p=0.0032) and 16 weeks (p=0.0038). No significant difference was observed in logMAR and CRT at any time point after IVTA between the two groups.

CONCLUSIONS

After an initial IVTA, increased IOP and ΔIOP from the baseline IOP were significantly more frequently observed in the non-vitrectomised than that in the vitrectomised group. IVTA is a safer and more effective treatment option for DME in vitrectomised than that in non-vitrectomised eyes.

摘要

目的

比较糖尿病及糖尿病性黄斑水肿(DME)患者行玻璃体腔注射曲安奈德(IVTA)后,玻璃体切除眼与未行玻璃体切除眼的眼内压(IOP)。

设计

回顾性对照研究。

方法

回顾性分析157例2型糖尿病患者(157只眼)因DME接受IVTA治疗的病历资料,比较玻璃体切除组与未行玻璃体切除组术前、IVTA后1周、4周、12周及24周的最佳矫正视力、IOP及光学相干断层扫描中心视网膜厚度(CRT)。

结果

未行玻璃体切除组在IVTA后1周(p<0.0001)、4周(p<0.0001)、8周(p<0.0001)、12周(p=0.0019)、16周(p=0.0006)及20周(p=0.0191)IOP显著升高,而行玻璃体切除组仅在1周(p=0.0003)及4周(p=0.0006)IOP显著升高。未行玻璃体切除组的ΔIOP(IOP相对于基线的变化)在4周(p=0.0014)、8周(p=0.0081)、12周(p=0.0032)及16周(p=0.0038)时显著高于行玻璃体切除组。两组在IVTA后任何时间点的logMAR及CRT均无显著差异。

结论

初次IVTA后,未行玻璃体切除组较行玻璃体切除组IOP升高及ΔIOP相对于基线IOP升高的情况更常见。对于DME,IVTA用于玻璃体切除眼比未行玻璃体切除眼更安全、有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e3/7798713/288c8e03244e/bmjophth-2020-000620f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e3/7798713/d3a7100a8a84/bmjophth-2020-000620f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e3/7798713/70cced435402/bmjophth-2020-000620f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e3/7798713/288c8e03244e/bmjophth-2020-000620f03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e3/7798713/d3a7100a8a84/bmjophth-2020-000620f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e3/7798713/70cced435402/bmjophth-2020-000620f02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f0e3/7798713/288c8e03244e/bmjophth-2020-000620f03.jpg

相似文献

1
Comparison of the intraocular pressure following an intravitreal triamcinolone acetonide injection for diabetic macula oedema in vitrectomised and non-vitrectomised eyes.玻璃体腔注射曲安奈德治疗糖尿病性黄斑水肿在已行玻璃体切割术和未行玻璃体切割术的眼中眼压的比较。
BMJ Open Ophthalmol. 2021 Jan 8;6(1):e000620. doi: 10.1136/bmjophth-2020-000620. eCollection 2021.
2
Comparison of 4 mg versus 20 mg intravitreal triamcinolone acetonide injections.玻璃体内注射4毫克与20毫克曲安奈德的比较。
Br J Ophthalmol. 2008 Jun;92(6):810-3. doi: 10.1136/bjo.2007.126227. Epub 2008 Apr 17.
3
Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema.玻璃体内注射贝伐单抗与玻璃体内注射曲安奈德联合黄斑格栅激光治疗弥漫性糖尿病性黄斑水肿。
Eye (Lond). 2010 Aug;24(8):1325-30. doi: 10.1038/eye.2010.23. Epub 2010 Mar 19.
4
A Randomized Trial Comparing Suprachoroidal and Intravitreal Injection of Triamcinolone Acetonide in Refractory Diabetic Macular Edema due to Epiretinal Membrane.一项比较脉络膜上腔注射与玻璃体内注射曲安奈德治疗视网膜前膜所致难治性糖尿病性黄斑水肿的随机试验。
J Ophthalmol. 2022 Jan 21;2022:7947710. doi: 10.1155/2022/7947710. eCollection 2022.
5
Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema.玻璃体内注射曲安奈德与贝伐单抗治疗糖尿病性黄斑水肿的短期效果比较。
Korean J Ophthalmol. 2011 Jun;25(3):156-60. doi: 10.3341/kjo.2011.25.3.156. Epub 2011 May 24.
6
Intravitreal and posterior subtenon triamcinolone acetonide in idiopathic bilateral uveitic macular oedema.玻璃体内及眼球筋膜囊下注射曲安奈德治疗特发性双侧葡萄膜炎性黄斑水肿
Clin Exp Ophthalmol. 2007 Nov;35(8):713-8. doi: 10.1111/j.1442-9071.2007.01578.x.
7
The effects of intravitreal triamcinolone acetonide in diabetic macular edema refractory to anti-VEGF treatment.玻璃体内曲安奈德治疗抗血管内皮生长因子治疗抵抗的糖尿病黄斑水肿的疗效。
Jpn J Ophthalmol. 2020 Mar;64(2):196-202. doi: 10.1007/s10384-019-00710-6. Epub 2020 Jan 3.
8
Efficacy of Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema After Vitrectomy.玻璃体腔注射曲安奈德治疗玻璃体切除术后糖尿病性黄斑水肿的疗效
J Ocul Pharmacol Ther. 2016 Jan-Feb;32(1):38-43. doi: 10.1089/jop.2015.0045. Epub 2015 Sep 1.
9
Intravitreal dexamethasone implant versus triamcinolone acetonide for macular oedema of central retinal vein occlusion: quantifying efficacy and safety.玻璃体内注射地塞米松植入物与曲安奈德治疗视网膜中央静脉阻塞性黄斑水肿:疗效和安全性的量化分析
Int J Retina Vitreous. 2018 Mar 26;4:13. doi: 10.1186/s40942-018-0114-2. eCollection 2018.
10
Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion.曲安奈德和贝伐单抗玻璃体腔注射治疗视网膜分支静脉阻塞所致黄斑水肿的前瞻性比较。
Acta Ophthalmol. 2013 Jun;91(4):318-24. doi: 10.1111/j.1755-3768.2011.02298.x. Epub 2011 Dec 1.

引用本文的文献

1
Guidelines from an expert panel for the management of diabetic macular edema in the Malaysian population.马来西亚人群糖尿病性黄斑水肿管理专家小组指南。
Int J Ophthalmol. 2023 May 18;16(5):712-720. doi: 10.18240/ijo.2023.05.07. eCollection 2023.

本文引用的文献

1
Association between Early Anatomic Response and Intraocular Pressure Change after Intravitreal Dexamethasone Implant: An Optical Coherence Tomography Study.玻璃体内注射地塞米松植入术后早期解剖学反应与眼压变化的相关性:一项光学相干断层扫描研究
J Clin Med. 2020 Aug 20;9(9):2692. doi: 10.3390/jcm9092692.
2
Effect of intravitreal triamcinolone acetonide injection at the end of vitrectomy for vitreous haemorrhage related to proliferative diabetic retinopathy.玻璃体切割术结束时玻璃体内注射曲安奈德治疗增生性糖尿病视网膜病变相关玻璃体积血的疗效。
Br J Ophthalmol. 2018 Oct;102(10):1351-1357. doi: 10.1136/bjophthalmol-2017-311377. Epub 2018 Jan 17.
3
Efficacy and safety of postvitrectomy intravitreal triamcinolone therapy for diabetic macular edema.
玻璃体切除术后玻璃体腔内注射曲安奈德治疗糖尿病性黄斑水肿的疗效与安全性
Eur J Ophthalmol. 2016 Aug 4;26(5):485-90. doi: 10.5301/ejo.5000768. Epub 2016 Mar 7.
4
Efficacy of Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema After Vitrectomy.玻璃体腔注射曲安奈德治疗玻璃体切除术后糖尿病性黄斑水肿的疗效
J Ocul Pharmacol Ther. 2016 Jan-Feb;32(1):38-43. doi: 10.1089/jop.2015.0045. Epub 2015 Sep 1.
5
Intraocular pressure rise is predictive of vision improvement after intravitreal triamcinolone acetonide for diabetic macular oedema: a retrospective analysis of data from a randomised controlled trial.眼内压升高可预测玻璃体内注射曲安奈德治疗糖尿病性黄斑水肿后的视力改善:一项随机对照试验数据的回顾性分析
BMC Ophthalmol. 2014 Oct 21;14:123. doi: 10.1186/1471-2415-14-123.
6
Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.为期三年的随机、假手术对照试验:地塞米松眼内植入物治疗糖尿病性黄斑水肿患者。
Ophthalmology. 2014 Oct;121(10):1904-14. doi: 10.1016/j.ophtha.2014.04.024. Epub 2014 Jun 4.
7
Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes.玻璃体内注射贝伐单抗在玻璃体切割眼中的药代动力学。
J Ocul Pharmacol Ther. 2013 Sep;29(7):612-8. doi: 10.1089/jop.2013.0009. Epub 2013 Jun 4.
8
Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE.雷珠单抗治疗糖尿病黄斑水肿的长期疗效:两项 III 期临床试验(RISE 和 RIDE)的 36 个月结果。
Ophthalmology. 2013 Oct;120(10):2013-22. doi: 10.1016/j.ophtha.2013.02.034. Epub 2013 May 22.
9
Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation.玻璃体内注射曲安奈德治疗黄斑水肿的并发症及眼压升高的预测因素。
Int J Ophthalmol. 2012;5(6):719-25. doi: 10.3980/j.issn.2222-3959.2012.06.13. Epub 2012 Dec 18.
10
Effect of vitrectomy on aqueous VEGF concentration and pharmacokinetics of bevacizumab in macaque monkeys.玻璃体切割术对食蟹猴房水中 VEGF 浓度和贝伐珠单抗药代动力学的影响。
Invest Ophthalmol Vis Sci. 2012 Aug 24;53(9):5877-80. doi: 10.1167/iovs.12-10164.